MicroRNA Regulation of Chronic Inflammation During Aging

NCT05392582 | Recruiting DMC

• 1 other identifier: 153158
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

This is an observational study enrolling healthy individuals aged 18-35 and 65y and older to determine the health of immune cells in the blood and how these cells create inflammation and effect health as we age. It is hoped that once the nature of this relationship has been discovered we can more effectively design therapies to reduce this inflammation. The enrollment goal is 40 participants. The study will occur over the course of 1 month which will include a screening visit and a second visit where the participants will undergo an oral glucose tolerance test, blood draws and leg strength \& exercise tests.

Conditions

Chronic Inflammation

Outcome Measures

Primary Outcomes (1)

• Inflammation

  IL-6 levels

  Determined in older adults and in younger adults at a single visit (baseline).

Study Arms (2)

Young

Young healthy adult participants

Older

Older healthy adult participants

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Healthy young and older adults

You may qualify if:

• Age between 18 - 35y; 65y and older
• BMI: \<30 kg/m2
• Ability to sign informed consent
• For older participant group: Clinical Frailty Scale score \< 3 and Mini-Cog score \> 3
• Good general medical health, ambulatory and in independent living setting

You may not qualify if:

• History of cardiovascular disease (e.g., CHF, CAD, MI, CVA)
• History of endocrine or metabolic disease such as hypo/hyperthyroidism and diabetes (Treated hypo/hyperthyroid for at least 6 months will be permitted)
• History of kidney disease or failure (CKD \> stage 4)
• History of vascular disease
• Uncontrolled hypertension - Elevated systolic pressure \>150 or a diastolic blood pressure \> 100
• Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma
• Chronic systemic corticosteroid use (≥ 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular/topical/inhaled therapeutic or physiologic doses of corticosteroids will be permitted)
• Chronic anti-inflammatory medication use (≥ 2 weeks) within 4 weeks of enrollment
• Chronic inflammatory conditions (e.g., Rheumatoid Arthritis, Crohn's, fibromyalgia, lupus, colitis) HIV, Hepatitis B and C
• History of stroke with motor disability
• A recent history (\<12 months) of GI bleed
• History of liver disease or AST/ALT 2 times above the normal limit
• History of respiratory disease (acute upper respiratory infection, history of chronic lung disease)
• Current smokers or current tobacco use
• Current pregnancy as determined by positive pregnancy test

Sponsors & Collaborators

• University of Utah: lead

Study Sites (1)

The University of Utah

Salt Lake City, Utah, 84112, United States

RECRUITING

Study Officials

• Micah Drummond

  The University of Utah

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Micah Drummond, PhD

CONTACT

801-213-2737; micah.drummond@hsc.utah.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: May 20, 2022
• First Posted: May 26, 2022
• Study Start: November 12, 2024
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): January 1, 2028
• Last Updated: December 5, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)